Page last updated: 2024-10-27

gabapentin and Akinetic-Rigid Variant of Huntington Disease

gabapentin has been researched along with Akinetic-Rigid Variant of Huntington Disease in 3 studies

Gabapentin: A cyclohexane-gamma-aminobutyric acid derivative that is used for the treatment of PARTIAL SEIZURES; NEURALGIA; and RESTLESS LEGS SYNDROME.
gabapentin : A gamma-amino acid that is cyclohexane substituted at position 1 by aminomethyl and carboxymethyl groups. Used for treatment of neuropathic pain and restless legs syndrome.

Research Excerpts

ExcerptRelevanceReference
"Huntington's disease is a progressive neurodegenerative disorder that gradually reduces memory, cognitive skills and normal movements of affected individuals."1.38Possible GABAergic mechanism in the neuroprotective effect of gabapentin and lamotrigine against 3-nitropropionic acid induced neurotoxicity. ( Kalonia, H; Kumar, A; Kumar, P, 2012)

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (66.67)29.6817
2010's1 (33.33)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Kumar, P1
Kalonia, H1
Kumar, A1
Zucker, B1
Ludin, DE1
Gerds, TA1
Lücking, CH1
Landwehrmeyer, GB1
Feuerstein, TJ1
Wu, J1
Tang, T1
Bezprozvanny, I1

Other Studies

3 other studies available for gabapentin and Akinetic-Rigid Variant of Huntington Disease

ArticleYear
Possible GABAergic mechanism in the neuroprotective effect of gabapentin and lamotrigine against 3-nitropropionic acid induced neurotoxicity.
    European journal of pharmacology, 2012, Jan-15, Volume: 674, Issue:2-3

    Topics: Amines; Animals; Body Weight; Brain; Catalase; Cyclohexanecarboxylic Acids; GABAergic Neurons; Gabap

2012
Gabapentin-lactam, but not gabapentin, reduces protein aggregates and improves motor performance in a transgenic mouse model of Huntington's disease.
    Naunyn-Schmiedeberg's archives of pharmacology, 2004, Volume: 370, Issue:2

    Topics: Amines; Animals; Anticonvulsants; Aza Compounds; Corpus Striatum; Cyclohexanecarboxylic Acids; Disea

2004
Evaluation of clinically relevant glutamate pathway inhibitors in in vitro model of Huntington's disease.
    Neuroscience letters, 2006, Oct-30, Volume: 407, Issue:3

    Topics: Amines; Animals; Apoptosis; Cells, Cultured; Cyclohexanecarboxylic Acids; Excitatory Amino Acid Anta

2006